ABSTRACT: The pregnane X receptor (PXR) regulates the metabolism and excretion of xenobiotics and endobiotics by regulating the expression of drug-metabolizing enzymes and transporters. The unique structure of PXR allows it to bind many drugs and drug leads, possibly causing undesired drug− drug interactions. Therefore, it is crucial to evaluate whether chemicals or drugs bind to PXR. Fluorescence-based assays are preferred because of their sensitivity and nonradioactive nature. On the basis of our previously characterized 4 (BODIPY FL vinblastine), a high-affinity PXR probe, we developed 20 (BODIPY FL vindoline) and showed that it is a novel and potent PXR fluorescent probe with K d of 256 nM in a timeresolved fluorescence resonance energy transfer (TR-FRET) binding assay with PXR. By using 20 (BODIPY FL vindoline) in the PXR TR-FRET assay, we obtained a more than 7-fold signal-to-background ratio and high signal stability (signal was stable for at least 120 min, and Z′-factor > 0.85 from 30 to 240 min). The assay can tolerate DMSO up to 2%. This assay has been used to evaluate a panel of PXR ligands for their PXR-binding affinities. The performance of 20 (BODIPY FL vindoline) in the PXR TR-FRET assay makes it an ideal PXR fluorescent probe, and the newly developed PXR TR-FRET assay with 20 (BODIPY FL vindoline) as a fluorescent probe is suitable for high-throughput screening to identify PXR-binding ligands.
■ INTRODUCTION
The pregnane X receptor (PXR) 1 is a major xenobiotic receptor that regulates the metabolism and excretion of xenobiotics and endobiotics by regulating the expression of drug-metabolizing enzymes and drug transporters. 1, 2 Expression of a PXR target gene is regulated by the binding of PXR to the promoter region of the target gene, such as cytochrome P450 3A4, a critical enzyme in the metabolism of more than 50% of all clinically prescribed drugs. 3 By affecting drug metabolism and distribution, changes in PXR activity can influence the therapeutic and toxicological response to drugs and potentially cause adverse drug−drug interactions. 4, 5 PXR activity is mainly regulated by direct ligand binding (and the unique structure of PXR allows many drugs and drug leads to bind to it), 4 although it can also be regulated by various cell signaling pathways. 5 Radioligand-binding assays, in the format of scintillation proximity assays, were initially used to investigate direct binding of PXR to ligands such as 1 (TO901317), 6 2 (NMTB), 7 and 3 (SR12813) 8−10 ( Figure  1 ). When Invitrogen offered the LanthaScreen time-resolved fluorescence resonance energy transfer (TR-FRET) pregnane X competitive binding assay kit containing the first PXR fluorescent probe (Fluormone PXR (SXR) Green), it was quickly used in multiple studies.
11 −20 However, this commercially available assay may not be optimal for studying ligand− PXR interactions because the chemical structure of Fluormone PXR (SXR) Green is proprietary information that is not publicly disclosed and Fluormone PXR (SXR) Green is available only as a component of the assay kit and at a prediluted concentration of 4 μM in 50% methanol/water. 21 Recently, we have discovered 4 (BODIPY FL vinblastine) ( Figure 1 ) to be a potent PXR fluorescent probe and successfully used it in a TR-FRET assay to evaluate the PXRbinding affinities of a panel of putative PXR ligands: 1 (TO901317), 3 (SR12813), 5 (hyperforin), 6 (clotrimazole), 7 (rifampicin), 8 (ginkgolide A), and 9 (ginkgolide B) ( Figure  1 ). 22 It was speculated that the unique combination of 10 (vinblastine) ( Figure 2 ) and 11 (BODIPY FL propionic acid) (Figure 2 ), which forms BODIPY FL vinblastine, contributes to the high PXR-binding affinity because 10 (vinblastine) itself has low PXR-specific binding affinity and 11 (BODIPY FL propionic acid) has no PXR-specific binding affinity by itself. 22 To identify additional novel and potent PXR fluorescent probes based on the high-affinity PXR probe BODIPY FL vinblastine, 22 we first inspected the PXR-binding activities of 10 (vinblastine), its close analogue 12 (deacetyl vinblastine), and its fragments 13 (catharanthine) and 14 (vindoline), together with 15 (catharanthinic acid) and 16 (deacetyl vindoline), which are the close analogues of 13 and 14, respectively ( . The typical reaction involved in preparing these probes was an EDAC-and DMAP-mediated Mitsunobu reaction 23 between carboxylic acid and primary amine in the synthesis of 19 (BODIPY FL catharanthine) and between carboxylic acids and secondary alcohol in the syntheses of 20 (BODIPY FL vindoline) and 21 (sulfo-Cy5 vindoline). In the preparation of 19 (BODIPY FL catharanthine), 15 (catharanthinic acid) was reacted with 17 (BODIPY FL propionyl ethylenediamine hydrochloride) for 6 h at room temperature and under nitrogen protection in the presence of EDAC, DMAP, and DIPEA with methylene chloride as the solvent and provided a yield of 18%. In the preparation of 20 (BODIPY FL vindoline), 16 (deacetyl vindoline) was reacted with 11 (BODIPY FL propionic acid) for 5 h at room temperature and under nitrogen protection in the presence of EDAC and DMAP with methylene chloride as the solvent and provided a yield of 74%. In the preparation of 21 (sulfo-Cy5 vindoline), 16 (deacetyl vindoline) was reacted with 18 (sulfo-Cy5 carboxylic acid) for 24 h at room temperature and under nitrogen protection in the presence of EDAC and DMAP with DMF as the solvent and provided a yield of 68%. In the preparation of 20 (BODIPY FL vindoline) and 21 (sulfo-Cy5 vindoline), the secondary hydroxyl group in deacetyl vindoline (16) was esterified because this secondary hydroxyl group has relatively higher reactivity than the other tertiary hydroxyl group in the deacetyl vindoline (16) due to less steric hindrance around the secondary hydroxyl group area. The selective reactivity of esterification at the secondary hydroxyl group in deacetyl vindoline (16) has been previously reported in a similar DCC and DMAP-mediated coupling reaction. 24 Evaluation of the hPXR-Binding Activities of Vinblastine (10), Deacetyl Vinblastine (12), Catharanthine (13), Catharanthinic Acid (15), Vindoline (14) , and Deacetyl Vindoline (16) . To investigate which portion of BODIPY FL vinblastine (4) is responsible for its high PXR-binding affinity, we determined the competitive binding activities of vinblastine (10) , its fragments catharanthine (13) and vindoline (14) , and their respective close analogues deacetyl vinblastine (12) , catharanthinic acid (15) , and deacetyl vindoline (16) in the BODIPY FL vinblastine (4)-based PXR TR-FRET binding assay, using TO901317 (1, 10 μM, 100% inhibition) and DMSO (0% inhibition) as positive and negative controls, respectively; the use of TO901317 (1, 10 μM) and DMSO as controls as well as the probe concentration of BODIPY FL vinblastine (100 nM) in the TR-FRET assay was previously described. 22 The fluorophore portion of BODIPY FL vinblastine, the BODIPY FL propionic acid (11), was not included in the test because it does not have any specific PXRbinding affinity. 22 The TR-FRET signals for each individual test condition were normalized to those of positive (100% inhibition) and negative (0% inhibition) controls and presented as the percent inhibition, with representative results summarized in Figure 6A and Table 1 . Among vinblastine (10) and its fragments catharanthine (13) and vindoline (14) , vindoline (14) displays the strongest competitive binding activity, inhibiting the binding of BODIPY FL vinblastine to PXR by 93% at 100 μM. By contrast, vinblastine (10) and catharanthine (13) have inhibitory activities of only 60 and 73%, respectively, at 100 μM. However, deacetyl vinblastine (12), catharanthinic acid (15) , and deacetyl vindoline (16) , which are the respective close and more-hydrophilic analogues of vinblastine (10), catharanthine (13) , and vindoline (14) , display less PXRbinding inhibitory activity (40, 44, and 73%, respectively) than do their corresponding parental analogues (60, 73, and 93%, respectively) at 100 μM. As shown in Figure 6A , the competitive binding activity of all compounds tested is dosedependent. These results suggest that the lipophilic modifications at respective positions (4-acetylations in vinblastine and vindoline; 18-methylesteration in catharanthine) are important to maintain high PXR-binding inhibitory activity. The dose−response curves and activities of those chemicals having a maximal percent inhibition greater than 50% are summarized in Figure 6B and Table 1 . Vindoline (14) has the highest PXR-binding inhibitory activity, with an IC 50 value of 12.9 μM. Vinblastine (10) and catharanthine (13) have IC 50 values of 71.4 and 20.5 μM, respectively. Among the respective close and more-hydrophilic analogues of vinblastine (10), catharanthine (13) and vindoline (14) (deacetyl vinblastine (12) , catharanthinic acid (15) , and deacetyl vindoline (16)), only deacetyl vindoline (16) has a percent inhibition greater than 50%, with an IC 50 value of 41.4 μM. The maximum inhibitory activities of deacetyl vinblastine (12) and catharanthinic acid (15) are less than 50%; therefore, no IC 50 value could be obtained. The positive control TO901317 (1) is a potent PXR binder with an IC 50 value of 304 nM.
The results discussed above indicate that in the BODIPY FL vinblastine (4)-based PXR TR-FRET binding assay, catharanthine (13) and vindoline (14) , the two fragments of vinblastine (10) , have stronger PXR competitive binding activities than does vinblastine (10) . In addition, the lipophilic modifications present in vinblastine (10), catharanthine (13) , and vindoline (14) enhance their PXR-binding activities beyond those of the corresponding deacetyl vinblastine (12) , catharanthinic acid (15) , and deacetyl vindoline (16) . Similarly, modification of deacetyl vinblastine (12) with the lipophilic BODIPY FL propionic acid (11) generates BODIPY FL vinblastine (4), a high-affinity PXR ligand with a K d of 673 nM, as previously reported. 22 On the basis of these observations, we hypothesized that similar lipophilic modifications with the proper fluorescent moiety at corresponding positions in catharanthinic acid (15) and especially deacetyl vindoline (16) might lead to novel and high-affinity PXR fluorescent probes. We therefore designed and synthesized BODIPY FL catharanthine (19) , BODIPY FL vindoline (20) , and sulfo-Cy5 vindoline (21) (Table 1 ). Both deacetyl vindoline (16) and deacetyl vinblastine (12) are substantially weaker than BODIPY FL vinblastine ( Figure 6 ). Similarly, 4-acetylation of deacetyl vindoline (16) generates a more lipophilic vindoline (14) , which demonstrated a stronger PXR-binding inhibitory activity [K i of 36.0 μM for deacetyl vindoline (16) and 11.2 μM for vindoline (14) ] (Table 1 ). There results indicate that proper modifications of deacetyl vindoline (16) enhance its PXR binding affinity. However, hydrophilic modification of deacetyl vindoline (16) at its 4-position with sulfo-Cy5 carboxylic acid (18) led to sulfo-Cy5 vindoline (21) , which displayed no specific PXR binding affinity. The loss of specific PXR binding affinity was also observed in BODIPY FL catharanthine (19) , in which catharanthinic acid (15) is modified at its 18-position with BODIPY FL EDA (17); however, 18-methylesteration of catharanthinic acid (15) led to catharanthine (13) with improved PXR-binding inhibitory activity ( Figure 6 ). Together these results suggest that the binding affinity of a compound to PXR can be differentially affected by different modifications.
In light of the fact that BODIPY FL vinblastine (4, K d of 297 nM) and BODIPY FL vindoline (20, K d of 256 nM) are higher- affinity hPXR ligands than their corresponding precursors deacetyl vinblastine (12) and deacetyl vindoline (16) and that BODIPY FL propionic acid (11) itself is not an hPXR ligand, 22 BODIPY FL vinblastine (4) and BODIPY FL vindoline (20) should be considered to be unique chemical entities in terms of their hPXR affinity.
Because higher PXR binding affinity was observed for BODIPY FL vinblastine (4) when PXR TR-FRET binding assays were performed with the newly formulated and clearly defined laboratory assay buffer (50 mM Tris, 50 mM KCl, 1 mM CHAPS, 0.1 mg/mL BSA, 0.05 mM DTT, pH 7.5) than with Invitrogen assay buffer, the components of which are a trade secret and not disclosed (K d of 297 and 673 nM, 22 respectively), we used only the newly formulated laboratory assay buffer in the hPXR TR-FRET assays from here on.
Determination of the Optimal BODIPY FL Vindoline To avoid deviating from the Cheng−Prusoff equation in any subsequent calculation of a compound's K i value, a concentration at or somewhat below the K d value of the probe should generally be tested. 25 Because the K d value of BODIPY FL vindoline (20) is 256 nM, the four concentrations of BODIPY FL vindoline (20) tested were 250, 100, 50, and 25 nM ( Figure  8A) . Each probe concentration was tested under four different treatment conditions to gain insight into the total binding of BODIPY FL vindoline (20) to hPXR (DMSO group), the background binding of BODIPY FL vindoline (20) to hPXR in the presence of TO901317 (1, 10 μM), the absolute background binding A (DMSO in the absence of GSThPXRLBD protein, but with the presence of GST), and the absolute background binding B (DMSO in the absence of both GST-hPXR-LBD and GST protein). Consistent with the data shown in Figure 7C , both total binding (DMSO group with GST-PXRLBD) and background binding (10 μM TO901317 with GST-PXRLBD) increased as the concentration of BODIPY FL vindoline (20) increased from 25 to 250 nM ( Figure 8A ).
To determine whether background BODIPY FL vindoline (20) binding is mediated by hPXR, we omitted hPXR protein from the assay. In the absence of GST-hPXRLBD but with GST (absolute background binding A; DMSO group in the absence of GST-hPXRLBD but with GST in Figure 8A (20) can bind weakly and nonspecifically to components of the assay system in an hPXR-independent manner, its binding to hPXR is specific and substantially higher than the background binding.
The ratio of total binding signal (DMSO negative control group) to background binding signal (10 μM TO901317 positive control group) for BODIPY FL vindoline (20) concentrations of 25, 50, 100, and 250 nM was 3.4, 4.4, 7.0 and 4.7, respectively ( Figure 8B ). Because the TR-FRET assay is robust and radiometric, all three signal-to-background ratios are suitable for a high-throughput screening (HTS) assay. In fact, with the Invitrogen PXR TR-FRET kit, HTS of 8280 chemicals was successfully accomplished, with signal-to-background ratios ranging from 2.5 to only 3.5 and Z′-factor > 0.5. 13 We chose 100 nM BODIPY FL vindoline (20) for further experimentation because of their signal-to-background ratio (the higher the better) and background binding (the lower the better). However, assays with 50 nM BODIPY FL vindoline (20) probe were also validated (data not shown), and it may be beneficial to evaluate some lower-affinity PXR ligands ( Figure  11B and Table 2 ).
Signal Figure 9A ) for the corresponding 30, 60, 90, 120, 180, and 240 min reaction times, with very stable signals at 120 min that slightly decreased after 120 min. Correspondingly, the signal-to-background ratios were also relatively stable, with a slightly decreasing trend over time ( Figure 9B) .
The Z′-factor remained constant over the entire testing period ( Figure 9C ). The IC 50 values for TO901317 (1) were relatively stable over the entire 240 min time course, with signals decreasing slightly after 120 min incubations ( Figure  9D ). The consistent Z′-factor values demonstrate that the assay is very stable and is suitable for HTS. Although all incubation times could be used for HTS, the signals and signal-tobackground ratios suggest an optimal incubation time of 120 min or less for the BODIPY FL vindoline (20) LBD, and 5 nM Tb-anti-GST. The total binding signal (at 10 000 × 520 nm:490 nm ratio) remained stable at 3404−3259 with DMSO concentrations of 0.2 to 2% and then decreased to 2906 and 2033 when the DMSO concentration was increased to 5 and 10%, respectively ( Figure 10A ). The background binding signal (in the presence of 10 μM of TO901317) remained constant at 476−490 with DMSO concentrations of 0.2 to 2% and then decreased slightly to 432 when the DMSO concentration was increased to 5 or 10% ( Figure 10A ). The signal-to-background ratio was also relatively stable, ranging from 6.8 to 7.0 at DMSO concentrations at or below 5% and falling to 4.7 when the DMSO concentration was 10% ( Figure  10B ). In the TO901317 (1) Table 2 ).
The PXR inhibitory activities of the seven ligands tested in this article along with literature-reported activities are summarized in Table 2 . In general, a lower probe concentration resulted in lower PXR inhibitory IC 50 values, although the shapes of the curves were quite similar regardless of probe concentrations. From this point, a lower BODIPY FL vindoline (20) concentration (50 instead of 100 nM) may be useful for evaluating relative lower-affinity PXR ligands and calculating their IC 50 values because more complete dose curves may be obtained (when high drug concentrations are used). However, compound solubility will limit the concentration range that can be used. For example, ginkgolide B (9) has a more complete dose−response curve with 50 nM BODIPY FL vindoline (20) than with 100 nM, so the IC 50 value of ginkgolide B (9) from tests with 50 nM BODIPY FL vindoline (20) might be more reliable. When ligand inhibitory activities obtained by using BODIPY FL vindoline (20) as the fluorescent probe were compared to those obtained by using BODIPY FL vinblastine (4) as the fluorescent probe, the general potency rank order was maintained, with TO901317 (1), SR12813 (3), and hyperforin (5) in a high potency group, clotrimazole (6) in a medium potency group, and rifampicin (7), ginkgolide A (8), and ginkgolide B (9) in a low potency group. The slight difference may be due to the fact that PXR has a relatively large and flexible ligand-binding pocket that can accommodate ligands of different sizes 26−33 and even a single ligand with different conformations. 27 With PXR having a large and flexible ligand-binding pocket, it may bind to BODIPY FL vindoline and BODIPY FL vinblastine with different conformations, resulting in a slightly different ligand potency rank order when different PXR fluorescent probes are used.
Co-crystal structures of hPXR and its ligands TO901317 (1), 26 SR12813 (3), 27, 28 hyperforin (5), 30 and rifampicin (7) 29 have been reported and demonstrate that these ligands bind directly to the ligand-binding pocket of PXR. The finding that PXR ligands TO901317 (1), SR12813 (3), hyperforin (5), and rifampicin (7) , and N,N-diisopropylethylamine (DIPEA, 33 mg/45 μL, 250 μmol) was dissolved in anhydrous methylene chloride (CH 2 Cl 2 , 10 mL), and the reaction was stirred at room temperature under nitrogen protection for 4 h until mass spectra indicated that the starting material 15 (catharanthinic acid) was not detectable. The reaction mixture was then diluted in methylene chloride (CH 2 Cl 2 , 50 mL) and washed twice with 20 mL of diluted hydrochloric acid brine (pH 5) and 20 mL sodium bicarbonate (7) 27.2 μM 8.4 μM 12.7 μM ginkgolide A (8) 37.7 μM 20.7 μM 13.7 μM ginkgolide B (9) 13.0 μM 10.4 μM 12.1 μM brine (pH 8). The remaining methylene chloride solution was dried by anhydrous sodium sulfate. The methylene chloride solution was then recovered by filtration, and methylene chloride was removed by an IKA RV 10 digital rotavapor (IKA Works, Inc., Wilmington, NC) to generate a deep-brown crude product. The crude product was then purified by using a preparative HPLC system using MS and UV directed fractionation. The column used was Phenomenex Gemini-NX C18, 50 × 30 mm, 5 μm. The fractions containing the product were pooled and evaporated to yield 19 (BODIPY FL catharanthine, 14.9 mg, 18% yield and 98.1% purity). 1 , and 4-(dimethylamino) pyridine (DMAP, 7.4 mg, 60 μmol) was dissolved in anhydrous methylene chloride (CH 2 Cl 2 , 5 mL), and the reaction was stirred at room temperature under nitrogen protection for 3 h until mass spectra indicated that the starting material 16 (deacetyl vindoline) was not detectable. The reaction mixture was then diluted in methylene chloride (CH 2 Cl 2 , 50 mL) and washed twice with 20 mL diluted sodium bicarbonate brine (pH 8). The remaining methylene chloride solution was dried by anhydrous sodium sulfate. The methylene chloride solution was then recovered by filtration, and methylene chloride was removed by an IKA RV 10 digital rotavapor to generate a brown crude product. The crude product was then purified by using a preparative HPLC system using MS and UV directed fractionation. The column used was Phenomenex Gemini-NX C18, 50 × 30 mm, 5 μm. The fractions containing the product were pooled and evaporated to yield 20 (BODIPY FL vindoline, 25.3 mg, 74% yield and 98.4% purity). , and 4-(dimethylamino) pyridine (DMAP, 7.4 mg, 60 μmol) was dissolved in anhydrous N,Ndimethylformamide (DMF, 5 mL), and the reaction was stirred at room temperature under nitrogen protection for 16 h until mass spectra indicated that the starting material 16 (deacetyl vindoline) was not detectable. The solvent DMF in the reaction mixture was then removed by an IKA RV 10 digital rotavapor under vacuum to yield a deep-blue reaction product. The crude product was partitioned between methylene chloride (80 mL) and diluted hydrochloric acid brine (pH 4, 30 mL). The methylene chloride layer was then washed once with 20 mL of diluted hydrochloric acid brine (pH 4). The remaining methylene chloride solution was dried by anhydrous sodium sulfate. The methylene chloride solution was then recovered by filtration, and methylene chloride was removed by an IKA RV 10 digital rotavapor to generate a deep-blue crude product. The crude product was then purified by using a preparative HPLC system using MS and UV directed fractionation. The column used was Phenomenex Gemini-NX C18, 50 × 30 mm, 5 μm. The fractions containing the product were pooled and evaporated to yield 21 (sulfo-Cy5 vindoline, 35.3 mg, 68% yield and 95.9% purity). General Biological Assay Procedure. All assays were carried out in either 20 μL of TR-FRET PXR (SXR) assay buffer with 0.05 mM DTT (Invitrogen buffer) or laboratory assay buffer (50 mM Tris, 50 mM KCl, 1 mM CHAPS, 0.1 mg/mL BSA, 0.05 mM DTT, pH 7.5) with 5 nM GST-hPXR-LBD and 5 nM Tb-anti-GST at room temperature (approximately 25°C) in 384-well black polypropylene plates unless specified otherwise, and all assays were performed in triplicate. All chemicals were solubilized in DMSO. The final DMSO concentration was 1.1% in all assays, with the exception of the DMSO tolerance test, in which DMSO concentrations are specified. In a typical assay, a chemical (solubilized in DMSO) diluted in Invitrogen buffer or laboratory assay buffer as a 2× working solution (containing 2% DMSO) was first dispensed (10 μL/well) into a 384-well plate, followed by dispensing of individual fluorescent probe solution (4× working solution in Invitrogen buffer or laboratory assay buffer with 0.4% DMSO; 5 μL/well) and a mixture of 20 nM GST-hPXR-LBD and 20 nM Tb-anti-GST solution (prepared in Invitrogen buffer or laboratory assay buffer; 5 μL/well), unless specified otherwise. After mixing all assay components by shaking them for 1 min on an IKA MTS 2/4 digital microtiter plate shaker (IKA Works; Wilmington, NC, USA), the plates were briefly centrifuged at 201g (1000 rpm) for 30 s in an Eppendorf 5810 centrifuge with an A-4-62 swing-bucket rotor (Eppendorf AG, Hamburg, Germany). The typical assay incubation time was 30 min, with the exception of the longitudinal signal stability assays, for which the incubation time is specified. All assay data were generated by using a PHERAstar FS plate reader (BMG Labtech; Durham, NC, USA) to measure fluorescent signal followed by calculation of the fluorescence emission ratio [10 000 × 520 nm/490 nm for BODIPY FL vinblastine (4), BODIPY FL catharanthine (19) , and BODIPY FL vindoline (20) and 10 000 × 665 nm/620 nm for sulfo-Cy5 vindoline (21) in the PXR binding assays] of each well, using a 340 nm excitation filter, 100 μs delay time, and 200 μs integration time. Raw data from the plate reader were directly used for analysis unless specified otherwise. The graphic software GraphPad Prism 5.04 (GraphPad Software; La Jolla, CA, USA) was used to generate graphs and curves and to determine K d and IC 50 values. The methods described here were applied to all of the specific assays described below; additional information is included in the description of each specific assay where applicable.
Inhibitory Activity of 1 (TO901317), 10 (Vinblastine), 12 (Deacetyl Vinblastine), 13 (Catharanthine), 15 (Catharanthinic Acid), 14 (Vindoline), and 16 (Deacetyl Vindoline) against 4 (BODIPY FL Vinblastine) in the 4 (BODIPY FL Vinblastine)-Based PXR TR-FRET Binding Assay. Serial dilutions of 1 (TO901317, 10 μM to 0.06 nM, 1:3 titration at 12 concentration levels), 10 (vinblastine), 12 (deacetyl vinblastine), 13 (catharanthine), 15 (catharanthinic acid), 14 (vindoline), 16 (deacetyl vindoline) (100 μM to 49 nM, 1:2 titration at 12 concentration levels), DMSO, or 10 μM TO901317 were incubated with 100 nM 4 (BODIPY FL vinblastine), 5 nM GST-hPXR-LBD, and 5 nM Tb-anti-GST in Invitrogen buffer for 30 min before TR-FRET signals (10 000 × 520 nm/490 nm) were collected. The data were normalized to positive control (10 μM TO901317, 100% inhibition) and negative control (DMSO, 0% inhibition) values, with eq 1 used to derive the percent inhibition of individual chemicals at respective concentrations. 
Where applicable, the data were fit into a one-site competitive binding equation to derive IC 50 values. The inhibition constant (K i ) value was subsequently calculated by using eq 2.
where IC 50 is the concentration of inhibitor that inhibits 50% of binding, Determination of Signal Stability for 20 (BODIPY FL Vindoline) in the hPXR TR-FRET Assay. 20 (BODIPY FL vindoline, 100 nM) was incubated with 5 nM GST-hPXR-LBD and 5 nM Tb-anti-GST plus either DMSO, 1 (TO901317, 10 μM), or serial dilutions of 1 (TO901317, 10 μM to 0.3 nM with 1-to-2 titration for 16 concentration levels) in laboratory assay buffer, and TR-FRET signals (10 000 × 520 nm/490 nm) were collected after 30, 60, 90, 120, 180, and 240 min. The final DMSO concentration in all samples was 1.1%. To calculate the Z′-factor, 16 data points were included in both the high-signal (DMSO, negative vehicle control to determine total binding) and the low-signal (10 μM TO901317, positive control to determine nonspecific binding) groups, and eq 3 was used. 
where σ + is the standard deviation of the negative control (DMSO) group, σ − is the standard deviation of the positive control (10 μM TO901317) group, mean + is the mean of the negative control (DMSO) group, and mean − is the mean of the positive control (10 μM TO901317) group. The data from TO901317 titration were fit into a one-site competition binding equation to derive IC 50 values.
DMSO Tolerance Test for the 20 (BODIPY FL Vindoline)-Based hPXR TR-FRET Assay. 20 (BODIPY FL vindoline, 100 nM) was incubated with 5 nM GST-hPXR-LBD and 5 nM Tbanti-GST plus either DMSO, 1 (TO901317, 10 μM), or serial dilutions of 1 (TO901317, 10 μM to 0.3 nM, with 1-to-2 titration at 16 concentration levels) in laboratory assay buffer. The final DMSO concentration was 0.2, 0.5, 1, 1.1, 2, 5, or 10% in each group. After a 30 min incubation, the TR-FRET signals (10 000 × 520 nm/490 nm) were collected. The data from titrated TO901317 were fit into a one-site competition binding equation to determine the IC 50 values.
Binding Affinity of hPXR Ligands 1 (TO901317), 3 (SR12813), 5 (Hyperforin), 6 (Clotrimazole), 7 (Rifampicin), 8 (Ginkgolide A), and 9 (Ginkgolide B) against hPXR in the 20 (BODIPY FL Vindoline)-Based hPXR TR-FRET Assay. Serial dilutions of 1 (TO901317), 3 (SR12813), 5 (hyperforin) (10 μM to 0.3 nM, with 1-to-2 titration at 16 concentration levels), 6 (clotrimazole), 7 (rifampicin), 8 (ginkgolide A), 9 (ginkgolide B) (100 μM to 49 nM, with 1-to-2 titration at 12 concentration levels), DMSO, or 10 μM TO901317 were incubated with 100 nM 20 (BODIPY FL vindoline), 5 nM GST-hPXR-LBD, and 5 nM Tb-anti-GST for 30 min in laboratory assay buffer before TR-FRET signals (10 000 × 520 nm/490 nm) were collected. Where applicable, the data were fit into a one-site competitive binding equation in a dosedependent manner to derive IC 50 values.
Statistical Analysis. Results are expressed as the mean ± standard deviation of at least three independent experiments. Sample and control values were compared by using Student's t test, and p ≤ 0.05 was considered to indicate a statistically significant difference.
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